Kymera Therapeutics (KYMR)
(Delayed Data from NSDQ)
$42.96 USD
-0.79 (-1.81%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $42.94 -0.02 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KYMR 42.96 -0.79(-1.81%)
Will KYMR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KYMR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KYMR
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
KYMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
Other News for KYMR
Kymera Therapeutics (KYMR) Gains Support as Data Release Approaches
Kymera Therapeutics transferred with Buy rating at B. Riley
Goldman Sachs Initiates Coverage on Kymera Therapeutics (KYMR) as Early-Stage Biotech | KYMR ...
Kymera Therapeutics initialed with Early-Stage Biotech at Goldman Sachs
Gilead sees Q2 EPS hit from IPR&D expenses